Nykode Therapeutics AS

OB:NYKD Stock Report

Market Cap: NOK 943.1m

Nykode Therapeutics Management

Management criteria checks 1/4

Nykode Therapeutics' CEO is Michael Engsig, appointed in Sep 2019, has a tenure of 5.25 years. directly owns 0.005% of the company’s shares, worth NOK45.74K. The average tenure of the management team and the board of directors is 2.9 years and 2.6 years respectively.

Key information

Michael Engsig

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure5.3yrs
CEO ownership0.005%
Management average tenure2.9yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Aug 05
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate

Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

Jan 22
Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)

We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Aug 20
We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth

Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

Apr 06
Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business

CEO Compensation Analysis

How has Michael Engsig's remuneration changed compared to Nykode Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$38m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023n/an/a

-US$35m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022n/an/a

-US$43m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$567kUS$330k

-US$9m

Sep 30 2021n/an/a

US$147m

Jun 30 2021n/an/a

US$146m

Mar 31 2021n/an/a

US$146m

Dec 31 2020US$424kUS$280k

US$150m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$113kUS$106k

-US$14m

Compensation vs Market: Insufficient data to establish whether Michael's total compensation is reasonable compared to companies of similar size in the Norwegian market.

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Engsig (52 yo)

5.3yrs

Tenure

US$567,000

Compensation

Mr. Michael Thyring Engsig is an Independent Director at FluoGuide A/S since March 21, 2023. He has been Chief Executive Officer of Nykode Therapeutics AS (formerly known as Vaccibody AS) since September 1...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Engsig
Chief Executive Officer5.3yrsUS$567.00k0.0049%
NOK 45.7k
Harald Gurvin
Chief Financial Officer3.6yrsno data0.0092%
NOK 86.7k
Ulrich Blaschke
Chief Technology Officerless than a yearno datano data
Agnete Fredriksen
Chief Scientific Officer & Business Developmentno datano datano data
Louise Stubbe
Chief Legal Officer2.9yrsno datano data
Klaus Edvardsen
Chief Research & Development Officer2.4yrsno datano data

2.9yrs

Average Tenure

50.5yo

Average Age

Experienced Management: NYKD's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernd Seizinger
Director10.9yrsUS$53.00k0.20%
NOK 1.9m
Einar Greve
Deputy Board Member2.6yrsUS$45.00k0.54%
NOK 5.1m
Alf Gunnar Nicklasson
Chairman of the Boardno dataUS$95.00k0.043%
NOK 410.1k
Trygve Lauvdal
Observer to the Boardno dataUS$13.00kno data
Christian Åbyholm
Director4.9yrsUS$50.00k0.66%
NOK 6.2m
Anne Michelle Whitaker
Director2.6yrsUS$50.00kno data
Birgitte Volck
Director3.6yrsUS$53.00k0.0062%
NOK 58.7k
Elaine Sullivan
Director2.6yrsUS$60.00kno data
Harald Arnet
Director1.6yrsUS$50.00k0.051%
NOK 485.2k

2.6yrs

Average Tenure

63yo

Average Age

Experienced Board: NYKD's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nykode Therapeutics AS is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Viktor SundbergABG Sundal Collier Sponsored
Geir HolomDNB Markets
Patrick TrucchioH.C. Wainwright & Co.